User profiles for "author:Ricardo Blanco"
Ricardo blanco alonsoHU Marqués de Valdecilla Verified email at humv.es Cited by 20167 |
Cutaneous vasculitis in children and adults: associated diseases and etiologic factors in 303 patients
R Blanco, VM Martínez-Taboada… - Medicine, 1998 - journals.lww.com
Cutaneous vasculitis (CV) is a condition characterized clinically mainly by palpable purpura,
involving predominantly the lower extremities, and histologically by leukocytoclastic …
involving predominantly the lower extremities, and histologically by leukocytoclastic …
[HTML][HTML] Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals Of Care for UveitiS (FOCUS) initiative
Topic An international, expert-led consensus initiative to develop systematic, evidence-
based recommendations for the treatment of noninfectious uveitis in the era of biologics …
based recommendations for the treatment of noninfectious uveitis in the era of biologics …
[HTML][HTML] Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers
R López-Mejías, S Castañeda… - Autoimmunity …, 2016 - Elsevier
Cardiovascular disease (CV) is the most common cause of premature mortality in patients
with rheumatoid arthritis (RA). This is the result of an accelerated atherosclerotic process …
with rheumatoid arthritis (RA). This is the result of an accelerated atherosclerotic process …
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors …
GR Burmester, R Blanco, C Charles-Schoeman… - The Lancet, 2013 - thelancet.com
Background Rheumatoid arthritis is a heterogeneous chronic disease, and no therapeutic
agent has been identified which is universally and persistently effective in all patients. We …
agent has been identified which is universally and persistently effective in all patients. We …
Henoch‐Schönlein purpura in adulthood and childhood. Two different expressions of the same syndrome
R Blanco, VM Martínez‐Taboada… - … : Official Journal of …, 1997 - Wiley Online Library
Objective. To assess the possible differences between children (⩽ 20 years) and adults (>
20 years) with Henoch-Schönlein purpura (HSP). Methods. A retrospective study of an …
20 years) with Henoch-Schönlein purpura (HSP). Methods. A retrospective study of an …
Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double‐blind treatment phase …
Objective To assess the efficacy and safety of tocilizumab plus methotrexate (MTX) versus
MTX alone in preventing structural joint damage and improving physical function and …
MTX alone in preventing structural joint damage and improving physical function and …
[HTML][HTML] Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors
D Gladman, W Rigby, VF Azevedo… - … England Journal of …, 2017 - Mass Medical Soc
Background Tofacitinib is an oral Janus kinase inhibitor that is under investigation for the
treatment of psoriatic arthritis. We evaluated tofacitinib in patients with active psoriatic …
treatment of psoriatic arthritis. We evaluated tofacitinib in patients with active psoriatic …
Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment
MA González‐Gay, R Blanco… - … : Official Journal of …, 1998 - Wiley Online Library
Objective To assess the features and therapeutic response of visual manifestations and
cerebrovascular accidents (CVA) in giant cell (temporal) arteritis (GCA) and to identify the …
cerebrovascular accidents (CVA) in giant cell (temporal) arteritis (GCA) and to identify the …
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study
Objectives The impact of inflammatory rheumatic diseases on COVID-19 severity is poorly
known. Here, we compare the outcomes of a cohort of patients with rheumatic diseases with …
known. Here, we compare the outcomes of a cohort of patients with rheumatic diseases with …
Efficacy and safety of upadacitinib monotherapy in methotrexate‐naive patients with moderately‐to‐severely active rheumatoid arthritis (SELECT‐EARLY): a …
R van Vollenhoven, T Takeuchi… - Arthritis & …, 2020 - Wiley Online Library
Objective The SELECT‐EARLY trial was undertaken to study the effect of upadacitinib, an
oral, reversible Janus kinase 1–selective inhibitor, as monotherapy in patients with …
oral, reversible Janus kinase 1–selective inhibitor, as monotherapy in patients with …